Eosinophilic Esophagitis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Ellodi, Aqilion, AstraZeneca, Calypso, BMS, ESOCAP, Pfizer

February 28 02:35 2023
Eosinophilic Esophagitis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Ellodi, Aqilion, AstraZeneca, Calypso, BMS, ESOCAP, Pfizer
Delveinsight Business Research LLP
As per DelveInsight, in the 7MM, the Eosinophilic Esophagitis market size was approximately USD 600 million in 2021, which is anticipated to grow by 2032. The Eosinophilic Esophagitis market is anticipated to evolve immensely in the coming years owing to the expected launch of emerging therapies such as Cendakimab (Bristol Myers Squibb), APT-1011 (Ellodi Pharmaceuticals), and Benralizumab (AstraZeneca) during the forecast period (2022–2032).

DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Eosinophilic Esophagitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Eosinophilic Esophagitis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Eosinophilic Esophagitis Market

Eosinophilic Esophagitis: An Overview

According to the American Academy of Allergy, Asthma, and Immunology (AAAAI), Eosinophilic Esophagitis represents a chronic, local immune-mediated disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus, clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation.

Clinical manifestations in infants and toddlers generally include vomiting, food refusal, choking with meals, and, less commonly, failure to thrive. Predominant symptoms in school-aged children and adolescents include dysphagia, food impaction, and choking/gagging with meals, particularly while eating coarse textures, whereas dysphagia is more common in adults. Other symptoms associated with Eosinophilic Esophagitis include abdominal/chest pain, vomiting, and regurgitation.

Eosinophilic Esophagitis Market Key Facts

  • The United States accounted for the largest market size of Eosinophilic Esophagitis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

  • Among EU5 countries, Germany had the highest market size, with nearly USD 24.4 million in 2021, followed by France, with around USD 17.9 million in 2021.

  • The total diagnosed prevalent patient population of Eosinophilic Esophagitis in the 7MM countries was more than 700,000+ cases in 2021.

  • As per the estimates, the US had the highest patient population of Eosinophilic Esophagitis in 2021.

  • Among the EU5 countries, Germany had the highest diagnosed patient population of Eosinophilic Esophagitis, with approximately 58,000+ cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed prevalent patient population of Eosinophilic Esophagitis, with nearly.

  • DUPIXENT (Regeneron Pharmaceuticals/Sanofi) is expected to be the most successful therapy among all other candidates and shall account for the highest market revenue in the coming years. 

Eosinophilic Esophagitis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Eosinophilic Esophagitis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Eosinophilic Esophagitis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Eosinophilic Esophagitis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Eosinophilic Esophagitis Epidemiology, Segmented by –

  • Diagnosed Prevalence of Eosinophilic Esophagitis in the 7MM (2019–2032)

  • Age-specific Cases of Eosinophilic Esophagitis in the 7MM (2019–2032)

  • Gender-specific Cases of Eosinophilic Esophagitis in the 7MM (2019–2032)

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Esophagitis market or expected to be launched during the study period. The analysis covers the Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Eosinophilic Esophagitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Eosinophilic Esophagitis Market Will Evolve and Grow by 2032 @ 


Eosinophilic Esophagitis Therapeutics Analysis

In May 2022, Regeneron Pharmaceuticals/Sanofi announced that US FDA had approved DUPIXENT (dupilumab) for the treatment of Eosinophilic Esophagitis in adults and pediatric patients 12 years and older.

Several major pharma and biotech companies are developing therapies for Eosinophilic Esophagitis. Currently, Ellodi Pharmaceuticals is leading the therapeutics market with its Eosinophilic Esophagitis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Eosinophilic Esophagitis Therapeutics Market Include:

Allakos, Aqilion, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Calypso Biotech, DBV Technologies, Dr Falk Pharma, Ellodi Pharmaceutical, EsoCap, GlaxoSmithKline, Kyowa Hakko Kirin, Landos Biopharma, Pfizer, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Serpin Pharma, Takeda, and many others.

Eosinophilic Esophagitis Drugs Covered in the Report Include:

  • APT-1011: Ellodi Pharmaceutical

  • AQ280: Aqilion

  • Benralizumab: AstraZeneca

  • CALY-002: Calypso Biotech

  • Cendakimab: BMS

  • ESO-101: ESOCAP

  • Estrasimod: Pfizer

  • IRL201104: Revolo Biotherapeutics

  • Lirentelimab: Allakos

  • Omilancor: Landos Biopharma

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Eosinophilic Esophagitis Competitive Intelligence Analysis

4. Eosinophilic Esophagitis Market Overview at a Glance

5. Eosinophilic Esophagitis Disease Background and Overview

6. Eosinophilic Esophagitis Patient Journey

7. Eosinophilic Esophagitis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Eosinophilic Esophagitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Eosinophilic Esophagitis Unmet Needs

10. Key Endpoints of Eosinophilic Esophagitis Treatment

11. Eosinophilic Esophagitis Marketed Products

12. Eosinophilic Esophagitis Emerging Drugs and Latest Therapeutic Advances

13. Eosinophilic Esophagitis Seven Major Market Analysis

14. Attribute Analysis

15. Eosinophilic Esophagitis Market Outlook (In US, EU5, and Japan)

16. Eosinophilic Esophagitis Access and Reimbursement Overview

17. KOL Views on the Eosinophilic Esophagitis Market

18. Eosinophilic Esophagitis Market Drivers

19. Eosinophilic Esophagitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Strategies

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author